# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
As part of this process, the Company is considering a wide range of options with a focus on maximizing shareholder value, inclu...
HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Predictive Oncology (NASDAQ:POAI) from Buy to Neutral.
Q3 2024 and Recent Highlights:Announced the results of an additional study that successfully demonstrated the long-term stabili...
Predictive Oncology (NASDAQ:POAI) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of...
HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on Predictive Oncology (NASDAQ:POAI) with a Buy ra...
Predictive Oncology (NASDAQ:POAI) reported quarterly losses of $(0.68) per share. This is a 30.61 percent increase over losses ...